CA245-0001

Phase 3, randomized, double-blind, multicenter study evaluating the combination of BMS-986489 (a fixed-dose combination of Nivolumab and BMS-986012) with carboplatin and etoposide versus the combination of Atezolizumab with carboplatin and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer (ES-SCLC).

Open at Paris since : 01/04/2025
Target : Adult
Phase : Phase III

Trial description

The primary objective of this study is to compare whether BMS-986489 FDC used in combination with chemotherapy helps people live longer than those receiving chemotherapy and atezolizumab.;The secondary objectives of this study are to compare the following parameters between the two treatment arms:;Disease-related symptoms;Safety (i.e., "side effects");Number of participants whose disease improves ("response rate");Duration of disease improvement ("duration of response");Length of time participants in each treatment group live before their disease worsens ("progression-free survival")

Url of the trial

Main investigator

NICOLAS GIRARD

Professeur - Médecin

Contact